By Don Mitchell

McMaster University researchers say recent trials in the study of an inexpensive antidepressant are showing signs of some effectiveness as a treatment for COVID-19.

The evaluation, with university scientists and researchers from CardResearch Cardiologia Assistencial e de Pesquisa LTDA in Brazil, say the use of Fluvoxamine has the potential to cut hospital admissions by 30 per cent when used on those infected with the coronavirus.

Professor Ed Mills with the faculty of health sciences says the team treated 738 randomly selected Brazilian COVID-19 patients with fluvoxamine and another 733 with a placebo for 28 days between Jan. 20 and Aug. 6 of this year.

continue reading here



Submit a Comment

Find more articles